3 active not recruiting, 3 completed, 1 recruiting. 6 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Active not recruiting 2, Recruiting 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow Unresectable Thyroid Gland Carcinoma: new trials by email Literature Review of Unresectable Thyroid Gland Carcinoma trials Research Report on Unresectable Thyroid Gland Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC Selpercatinib, Sodium Iodine I-131, rhTSH - Thyroid Cancer, Thyroid Carcinoma | Phase 2 | Recruiting | Massachusetts General Hospital | 30 | 2023-03-01 | 2024-12-12 |
| Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer Lenvatinib, Pembrolizumab - Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 25 | 2021-11-04 | 2026-08-10 |
| Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) Laboratory Biomarker Analysis, Lenvatinib, Lenvatinib Mesylate - Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma | Phase 2 | Completed | Academic and Community Cancer Research United | 57 | 2018-02-07 | 2025-08-29 |
| Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer Atezolizumab, Bevacizumab, Cobimetinib - Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 50 | 2017-07-27 | 2026-07-24 |
| Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Thyroid Gland Carcinoma, Unresectable Thyroid Gland Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 23 | 2013-09-27 | 2026-05-14 |
| Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Cediranib, Cediranib Maleate, Laboratory Biomarker Analysis - Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 127 | 2010-09-09 | 2021-07-15 |
| Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Pharmacogenomic Study, Sunitinib - Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 63 | 2006-08-29 | 2025-03-28 |
Thyroid Neoplasms (5) · Adenocarcinoma, Follicular (4) · Thyroid Cancer, Papillary (4) · Thyroid Carcinoma, Anaplastic (2) · Thyroid cancer, Hurthle cell (2) · Carcinoma, Medullary (1)
Endocrine Gland Neoplasms (7) · Endocrine System Diseases (7) · Head and Neck Neoplasms (7) · Neoplasms (7) · Neoplasms by Site (7) · Thyroid Diseases (7) · Carcinoma (6) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6) · Adenocarcinoma (4) · Adenocarcinoma, Papillary (4) · Thyroid Neoplasms (2) · Carcinoma, Neuroendocrine (1) · Neoplasms, Ductal, Lobular, and Medullary (1) · Neoplasms, Germ Cell and Embryonal (1)
lenvatinib (2) · pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Biopsy (1) · Disulfides (1) · Immunoglobulin G (1) · Iodine-131 (1) · Lapatinib (1) · Lenalidomide (1) · Magnetic Resonance Spectroscopy (1) · N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine (1) · Paclitaxel (1) · Pharmacogenomic Testing (1)
National Cancer Institute (NCI) (3) · M.D. Anderson Cancer Center (2) · Academic and Community Cancer Research United (1) · Massachusetts General Hospital (1)
United States (7) · Canada (1)
Maria E Cabanillas (2) · Bryan R Haugen (1) · Chih-Yi Liao (1) · Eric J Sherman (1) · Lori J. Wirth, MD (1) · Tanguy Y Seiwert (1)
PMID 33720068, PMID 39446377, PMID 42673705
N01CM62201 (2), P30CA014599 (2), N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM62202 (1), P30CA008748 (1), P30CA015083 (1), U01CA069856 (1), U10CA180821 (1)